Researchers sought to determine whether subcutaneous isatuximab would be an effective treatment for patients with RRMM.
Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...
With three-quarters of a century dedicated to advancing cardiovascular science and improving patient care, the ESC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback